论文部分内容阅读
本文总结了选择性β２受体激动剂——博利康尼对支气管哮喘的临床疗效观察。结果表明，治疗组在博利康尼治疗后，短期内主要临床指标改善，显效率为７６．２％，总有效率９０．５％：对照组，显效５２．３％，总有效率６１．８％，明显优于对照组。
This article summarizes the clinical observation of bronchial asthma as a selective β2-agonist. The results showed that in the treatment group, the main clinical indexes were improved in the short term after the treatment with boliconi. The effective rate was 76.2% and the total effective rate was 90.5%. In the control group, the effective rate was 52.3% and the total effective rate was 61.8 %, Significantly better than the control group.